ReviewFrontiers in immunology2022
Latent autoimmune diabetes in adults in China.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Upregulation of ADAM19 in dendritic cells is associated with immune features and lower C-peptide levels in type 1 diabetes mellitus.Diabetology & metabolic syndrome · 2026Article
- Latent autoimmune diabetes in Saudi adults aged 30-55 years old seen at a tertiary hospital in Riyadh, Saudi Arabia.Journal of family medicine and primary care · 2026Article
- Explainable machine learning model for in-hospital hypoglycemia risk in patients with latent autoimmune diabetes in adults.Frontiers in immunology · 2026Article
- Autoimmune Phenotype Confirmation Intervals and Clinical Indicators in Patients With Latent Autoimmune Diabetes in Adults (LADA) in Southwest China: A Multicenter Retrospective Cross-Sectional Study.Journal of diabetes research · 2026Observational
- Analysis of risk factors and establishment of a prediction model for latent autoimmune diabetes in adults.Therapeutic advances in endocrinology and metabolism · 2026Article
- Metabolic-epigenetic crosstalk in latent autoimmune diabetes in adults: potential roles of lactate-induced histone lactylation in immune regulation and pancreatic β-cell fate.Frontiers in endocrinology · 2026Review
- Incidence of type 1 diabetes in Gansu Province, Northwest China from 2018 to 2022: a multicenter, hospitalization-based study.Acta diabetologica · 2025Article
- A case report of familial type 2 diabetes mellitus combined with hypothyroidism and multiple autoimmune diseases.Frontiers in endocrinology · 2025Article
- Phenome-Wide Association Study of Latent Autoimmune Diabetes from a Southern Mexican Population Implicates rs7305229 with Plasmatic Anti-Glutamic Acid Decarboxylase Autoantibody (GADA) Levels.International journal of molecular sciences · 2024Article
- Clinical value of lymphocyte count in autoimmune diabetic nephropathy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Article
- Against the Grain: Insulinoma-Associated Protein 2 Positive Latent Autoimmune Diabetes in Adults Defying Ethnic Prevalence Trends.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent autoimmune diabetes in adults (LADA) is a type of diabetes caused by slow progression of autoimmune damage to pancreatic beta cells. According to the etiological classification, LADA should belong to the autoimmune subtype of type 1 diabetes (T1D). Previous studies have found general immune genetic effects associated with LADA, but there are also some racial differences. Multicenter studies have been conducted in different countries worldwide, but it is still unclear how the Chinese and Caucasian populations differ. The epidemiology and phenotypic characteristics of LADA may vary between Caucasian and Chinese diabetic patients as lifestyle, food habits, and body mass index differ between these two populations. The prevalence of LADA in China has reached a high level compared to other countries. The prevalence of LADA in China has reached a high level compared to other countries, and the number of patients with LADA ranks first in the world. Previous studies have found general immune genetic effects associated with LADA, but some racial differences also exist. The prevalence of LADA among newly diagnosed type 2 diabetes patients over the age of 30 years in China is 5.9%, and LADA patients account for 65% of the newly diagnosed T1D patients in the country. As a country with a large population, China has many people with LADA. A summary and analysis of these studies will enhance further understanding of LADA in China. In addition, comparing the similarities and differences between the Chinese and the Caucasian population from the perspectives of epidemiology, clinical, immunology and genetics will help to improve the understanding of LADA, and then promote LADA studies in individual populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.